Recommendation of the President – Forxiga (dapagliflozin)
On 10 January 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 3/2025 on the inclusion in reimbursement of the medicinal product Forxiga (dapagliflozin) in the indication: chronic heart failure in adult patients with LVEF>50%, left ventricular hypertrophy or left atrial enlargement and NT-proBNP concentration ≥ 300 pg/ml (or ≥ 600 pg/ml in patients with atrial fibrillation or atrial flutter) and persistent symptoms of NYHA class II-IV disease
Publication in Public Information Bulletin (BIP) >>